Citarinostat | ACY241 | HDAC6 Inhibitor | AmBeed-信号通路专用抑制剂

Citarinostat/西他司他 {[allProObj[0].p_purity_real_show]}

货号：A207811 同义名： ACY241; HDAC-IN-2

Citarinostat是一种选择性HDAC6抑制剂，IC50为4 nM。它还可以抑制HDAC3（IC50 = 76 nM）。

Citarinostat/西他司他化学结构
CAS号：1316215-12-9

Citarinostat/西他司他 3D分子结构
CAS号：1316215-12-9

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

组蛋白去乙酰化酶亚型比较

产品名称	HD1 ↓ ↑	HD2 ↓ ↑	HDAC ↓ ↑	HDAC1 ↓ ↑	HDAC10 ↓ ↑	HDAC11 ↓ ↑	HDAC2 ↓ ↑	HDAC3 ↓ ↑	HDAC4 ↓ ↑	HDAC5 ↓ ↑	HDAC6 ↓ ↑	HDAC7 ↓ ↑	HDAC8 ↓ ↑	HDAC9 ↓ ↑	其他靶点	纯度
Givinostat HCl monohydrate	++++ HD1-B, IC50: 7.5 nM HD1-A, IC50: 16 nM	+++ HD2, IC50: 10 nM														99%+
MC1568	++ HD1-B (Maize), IC50: 3.4 μM HD1-A (Maize), IC50: 100 nM															96%
Trichostatin A			++++ HDAC, IC50: ~1.8 nM													99%+
Scriptaid			✔													99%+
Valproic acid sodium			✔												Autophagy	97%
AR-42			+++ HDAC, IC50: 30 nM													99%+
Dacinostat			+++ HDAC, IC50: 32 nM													98+%
CUDC-101			++++ HDAC, IC50: 4.4 nM	++++ HDAC1, IC50: 4.5 nM	+++ HDAC10, IC50: 26.1 nM		+++ HDAC2, IC50: 12.6 nM	++++ HDAC3, IC50: 9.1 nM	+++ HDAC4, IC50: 13.2 nM	+++ HDAC5, IC50: 11.4 nM	++++ HDAC6, IC50: 5.1 nM	+ HDAC7, IC50: 373 nM	++ HDAC8, IC50: 79.8 nM	++ HDAC9, IC50: 67.2 nM	EGFR,HER2	99%+
M344			++ HDAC, IC50: 100 nM													99%+
Splitomicin			+ Sir2p, IC50: 60 μM													99%
Panobinostat			++++ HDAC (Reh cells), IC50: 20 nM HDAC (MOLT-4 cells), IC50: 5 nM													98%
Sodium 4-Phenylbutyrate			✔													98%
Vorinostat			+++ HDAC, IC50: ~10 nM													98%
Curcumin			✔												Nrf2,NF-κB	98%
Belinostat			+++ HDAC, IC50: 27 nM													98%
RG-2833				++ HDAC1, Ki: 32 nM				++ HDAC3, Ki: 5 nM								98%
Valproic acid				+ HDAC1, IC50: 0.4 mM												98%
BG45				+ HDAC1, IC50: 2 μM			+ HDAC2, IC50: 2.2 μM	+ HDAC3, IC50: 289 nM								99%+
Entinostat				+ HDAC1, IC50: 0.51 μM				+ HDAC3, IC50: 1.7 μM								98%
Resminostat				+++ HDAC1, IC50: 42.5 nM				++ HDAC3, IC50: 50.1 nM			++ HDAC6, IC50: 71.8 nM					98+%
Romidepsin				+++ HDAC1, IC50: 36 nM			+++ HDAC2, IC50: 47 nM									99%+
Parthenolide				✔											NF-κB,p53	97% HPLC
Tacedinaline				+ HDAC1, IC50: 0.9 μM			+ HDAC2, IC50: 0.9 μM	+ HDAC3, IC50: 1.2 μM								98%
Mocetinostat				++ HDAC1, IC50: 0.15 μM		+ HDAC11, IC50: 0.59 μM	+ HDAC2, IC50: 0.29 μM	+ HDAC3, IC50: 1.66 μM								98%
WT-161				++++ HDAC1, IC50: 8.35 nM			+++ HDAC2, IC50: 15.4 nM				++++ HDAC6, IC50: 0.4 nM					99%+
Fimepinostat				++++ HDAC1, IC50: 1.7 nM	++++ HDAC10, IC50: 2.8 nM	++++ HDAC11, IC50: 5.4 nM	++++ HDAC2, IC50: 5.0 nM	++++ HDAC3, IC50: 1.8 nM			+++ HDAC6, IC50: 27 nM					99%+
Tucidinostat				++ HDAC1, IC50: 95 nM	++ HDAC10, IC50: 78 nM		++ HDAC2, IC50: 160 nM	++ HDAC3, IC50: 67 nM								99%+
Santacruzamate A							++++ HDAC2, IC50: 119 pM									99%+
(E,E)-RGFP966								++ HDAC3, IC50: 80 nM								99%+
LMK-235									+++ HDAC4, IC50: 11.9 nM	++++ HDAC5, IC50: 4.2 nM						99%+
Tasquinimod									✔							99%+
CAY10603											++++ HDAC6, IC50: 2 pM					98%
Tubastatin A											+++ HDAC6, IC50: 15 nM					98%
Tubacin											++++ HDAC6, IC50: 4 nM					99%+
ACY-738											++++ HDAC6, IC50: 1.7 nM					99%+
Nexturastat A											++++ HDAC6, IC50: 5 nM					99%+
BRD73954											+++ HDAC6, IC50: 36 nM		++ HDAC8, IC50: 120 nM			99%
Tubastatin A HCl											+++ HDAC6, IC50: 15 nM		+ HDAC8, IC50: 854 nM			98%
PCI-34051													+++ HDAC8, IC50: 10 nM			99%+
Ricolinostat				++ HDAC1, IC50: 58 nM			++ HDAC2, IC50: 48 nM	++ HDAC3, IC50: 51 nM			++++ HDAC6, IC50: 4.7 nM		++ HDAC8, IC50: 100 nM			99%+
Droxinostat								+ HDAC3, IC50: 16.9 μM			+ HDAC6, IC50: 2.47 μM		+ HDAC8, IC50: 1.46 μM			99%+
Abexinostat				++++ HDAC1, Ki: 7 nM	+++ HDAC10, IC50: 24 nM		+++ HDAC2, Ki: 19 nM	++++ HDAC3/SMRT, Ki: 8.2 nM			+++ HDAC6, Ki: 17 nM		+ HDAC8, IC50: 280 nM			98%+
Citarinostat				+++ HDAC1, IC50: 35 nM			+++ HDAC2, IC50: 45 nM	+++ HDAC3, IC50: 46 nM			++++ HDAC6, IC50: 2.6 nM		++ HDAC8, IC50: 137 nM			99%+
HPOB				+ HDAC1, IC50: 2.9 μM	+ HDAC10, IC50: 3.0 μM		+ HDAC2, IC50: 4.4 μM	+ HDAC3, IC50: 1.7 μM			++ HDAC6, IC50: 56 nM		+ HDAC8, IC50: 2.8 μM			97%
Quisinostat 2HCl				++++ HDAC1, IC50: 0.11 nM	++++ HDAC10, IC50: 0.46 nM	++++ HDAC11, IC50: 0.37 nM	++++ HDAC2, IC50: 0.33 nM	++++ HDAC3, IC50: 4.86 nM	++++ HDAC4, IC50: 0.64 nM	++++ HDAC5, IC50: 3.69 nM			++++ HDAC8, IC50: 4.26 nM			97%
Domatinostat				+ HDAC1, IC50: 1.20 μM	+ HDAC10, IC50: 21 μM	+ HDAC11, IC50: 9.7 μM	+ HDAC2, IC50: 1.12 μM	+ HDAC3, IC50: 0.57 μM		+ HDAC5, IC50: 11.3 μM				+ HDAC9, IC50: 50 μM		99%+
TMP269									++ HDAC4, IC50: 157 nM	++ HDAC5, IC50: 97 nM		+++ HDAC7, IC50: 43 nM		+++ HDAC9, IC50: 23 nM		99%+
Pracinostat				++ HDAC1, IC50: 49 nM	+++ HDAC10, IC50: 40 nM	++ HDAC11, IC50: 93 nM	++ HDAC2, IC50: 96 nM	+++ HDAC3, IC50: 43 nM	++ HDAC4, IC50: 56 nM	+++ HDAC5, IC50: 47 nM	+ HDAC6, IC50: 1.008 μM	++ HDAC7, IC50: 137 nM	++ HDAC8, IC50: 140 nM	++ HDAC9, IC50: 70 nM		99%+
TMP195									++ HDAC4, Ki: 59 nM	++ HDAC5, Ki: 60 nM		+++ HDAC7, Ki: 26 nM		+++ HDAC9, Ki: 15 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Citarinostat/西他司他生物活性

靶点

HDAC8

HDAC8, IC50:137 nM
HDAC3

HDAC3, IC50:46 nM
HDAC6

HDAC6, IC50:2.6 nM
HDAC2

HDAC2, IC50:45 nM
HDAC1

HDAC1, IC50:35 nM

描述

Citarinostat (ACY241) is an orally available, and highly selective inhibitor of HDAC6, showing an IC50 of 2.6 nM. Its selectivity extends across other HDAC isoforms as well, with IC50 values of 35 nM, 45 nM, 46 nM, and 137 nM for HDAC1, HDAC2, HDAC3, and HDAC8, respectively, suggesting its potential for anticancer applications^[1].

体内研究

Furthermore, in vivo studies reveal that Citarinostat, dosed at 50 mg/kg via intraperitoneal injection once daily for five days followed by a two-day break for three weeks, significantly inhibits tumor growth. This effect is observed in female athymic nude mice when Citarinostat is used in conjunction with NSC 125973, highlighting its therapeutic potential in cancer treatment when possibly combined with other anticancer agents.

体外研究

When administered to A2780 cells at a concentration of 300 nM for 24 hours, Citarinostat leads to notable hyperacetylation of α-tubulin, indicating the inhibition of HDAC6's tubulin deacetylase activity. Conversely, significant hyperacetylation of histone H3, a Class I HDAC target, is observed only at concentrations exceeding 1 μM. This delineates Citarinostat's capability for selective inhibition of HDAC6 at lower doses, while higher doses inhibit Class I HDAC isozymes^[1].

In terms of cytotoxicity, Citarinostat's IC50 values span from 4.6 to 6.1 μM in A2780 and TOV-21G ovarian cancer cells, as well as in MDA-MB-231 breast cancer cells. The data indicate that lower doses of Citarinostat up to 3 μM modestly reduce cell proliferation without triggering apoptosis. However, a higher dose of 10 μM markedly induces apoptosis and entirely halts proliferation^[1].

Citarinostat/西他司他细胞实验

Cell Line S1 cells MM.1s KP lung cancer cells CD4+ CD127loCD25+ Tregs R482-HEK293 cells MDR19-HEK293 cells HEK293 cells S1-M1-80 cells KB-V-1 cells KB-3-1 cells T-cells from melanoma patient PBMCs Granta-519 WSU-NHL	Concentration	Treated Time	Description	References
S1 cells	2.82 ± 0.40 µM	72 hours	Evaluate the cytotoxicity of Citarinostat on S1 cells	Int J Mol Sci. 2021 Mar 5;22(5):2592.
MM.1s	100-500 nM	18 hours	To evaluate the selectivity of ACY-241 in MM cells. Results showed that ACY-241 selectively increased acetylation of α-Tubulin at low concentrations and increased acetylation of Histone-H3 at higher concentrations.	PLoS One. 2017 Mar 6;12(3):e0173507.
KP lung cancer cells	10 µg/ml	36 hours	To evaluate the effect of ACY241 and Oxaliplatin on the effector function of tumor-associated T cells, results showed that ACY241 or Oxaliplatin alone enhanced the ability of CD8+ T cells to secrete TNFα and IFNγ, and the combination treatment had a more pronounced effect.	Oncoimmunology. 2022 Feb 22;11(1):2042065.
CD4+ CD127loCD25+ Tregs	500nM	72 hours	To evaluate the impact of HDAC6-selective inhibitors on regulatory T-cells (Tregs). Results showed that ACY-241 reduced Treg frequencies and FOXP3 expression and decreased their suppressive function.	J Immunother Cancer. 2019 Feb 6;7(1):33.
R482-HEK293 cells	20.11 ± 2.48 µM	72 hours	Evaluate the cytotoxicity of Citarinostat on R482-HEK293 cells	Int J Mol Sci. 2021 Mar 5;22(5):2592.
MDR19-HEK293 cells	33.83 ± 3.21 µM	72 hours	Evaluate the cytotoxicity of Citarinostat on MDR19-HEK293 cells	Int J Mol Sci. 2021 Mar 5;22(5):2592.
HEK293 cells	3.01 ± 0.44 µM	72 hours	Evaluate the cytotoxicity of Citarinostat on HEK293 cells	Int J Mol Sci. 2021 Mar 5;22(5):2592.
S1-M1-80 cells	59.66 ± 10.32 µM	72 hours	Evaluate the cytotoxicity of Citarinostat on S1-M1-80 cells	Int J Mol Sci. 2021 Mar 5;22(5):2592.
KB-V-1 cells	57.96 ± 5.56 µM	72 hours	Evaluate the cytotoxicity of Citarinostat on KB-V-1 cells	Int J Mol Sci. 2021 Mar 5;22(5):2592.
KB-3-1 cells	3.98 ± 0.73 µM	72 hours	Evaluate the cytotoxicity of Citarinostat on KB-3-1 cells	Int J Mol Sci. 2021 Mar 5;22(5):2592.
T-cells from melanoma patient PBMCs	500nM	72 hours	To evaluate the impact of HDAC6-selective inhibitors on T-cell viability and function. Results showed that ACY-241 did not impair T-cell viability at concentrations up to 1uM and reduced Th2 cytokine production (i.e. IL-4, IL-5, IL-6, IL-10 and IL-13).	J Immunother Cancer. 2019 Feb 6;7(1):33.
Granta-519	0, 0.5, 1, 2, 4 µM	24-48 hours	To evaluate the cytotoxicity of Citarinostat and Momelotinib alone and in combination on Granta-519 cells. Results showed that Granta-519 cells were less sensitive to the combination treatment (CI > 1), exhibiting an antagonistic effect.	Apoptosis. 2020 Jun;25(5-6):370-387.
WSU-NHL	0, 0.5, 1, 2, 4 µM	24-48 hours	To evaluate the cytotoxicity of Citarinostat and Momelotinib alone and in combination on lymphoid malignant cell lines. Results showed that the combination of Citarinostat and Momelotinib exhibited synergistic effects (CI < 1) in most cell lines, significantly inhibiting cell viability and inducing apoptosis.	Apoptosis. 2020 Jun;25(5-6):370-387.

Cell Line

Concentration

Treated Time

Description

References

S1 cells

2.82 ± 0.40 µM

72 hours

Evaluate the cytotoxicity of Citarinostat on S1 cells

Int J Mol Sci. 2021 Mar 5;22(5):2592.

MM.1s

100-500 nM

18 hours

To evaluate the selectivity of ACY-241 in MM cells. Results showed that ACY-241 selectively increased acetylation of α-Tubulin at low concentrations and increased acetylation of Histone-H3 at higher concentrations.

PLoS One. 2017 Mar 6;12(3):e0173507.

KP lung cancer cells

10 µg/ml

36 hours

To evaluate the effect of ACY241 and Oxaliplatin on the effector function of tumor-associated T cells, results showed that ACY241 or Oxaliplatin alone enhanced the ability of CD8+ T cells to secrete TNFα and IFNγ, and the combination treatment had a more pronounced effect.

Oncoimmunology. 2022 Feb 22;11(1):2042065.

CD4+ CD127loCD25+ Tregs

500nM

72 hours

To evaluate the impact of HDAC6-selective inhibitors on regulatory T-cells (Tregs). Results showed that ACY-241 reduced Treg frequencies and FOXP3 expression and decreased their suppressive function.

J Immunother Cancer. 2019 Feb 6;7(1):33.

R482-HEK293 cells

20.11 ± 2.48 µM

72 hours

Evaluate the cytotoxicity of Citarinostat on R482-HEK293 cells

Int J Mol Sci. 2021 Mar 5;22(5):2592.

MDR19-HEK293 cells

33.83 ± 3.21 µM

72 hours

Evaluate the cytotoxicity of Citarinostat on MDR19-HEK293 cells

Int J Mol Sci. 2021 Mar 5;22(5):2592.

HEK293 cells

3.01 ± 0.44 µM

72 hours

Evaluate the cytotoxicity of Citarinostat on HEK293 cells

Int J Mol Sci. 2021 Mar 5;22(5):2592.

S1-M1-80 cells

59.66 ± 10.32 µM

72 hours

Evaluate the cytotoxicity of Citarinostat on S1-M1-80 cells

Int J Mol Sci. 2021 Mar 5;22(5):2592.

KB-V-1 cells

57.96 ± 5.56 µM

72 hours

Evaluate the cytotoxicity of Citarinostat on KB-V-1 cells

Int J Mol Sci. 2021 Mar 5;22(5):2592.

KB-3-1 cells

3.98 ± 0.73 µM

72 hours

Evaluate the cytotoxicity of Citarinostat on KB-3-1 cells

Int J Mol Sci. 2021 Mar 5;22(5):2592.

T-cells from melanoma patient PBMCs

500nM

72 hours

To evaluate the impact of HDAC6-selective inhibitors on T-cell viability and function. Results showed that ACY-241 did not impair T-cell viability at concentrations up to 1uM and reduced Th2 cytokine production (i.e. IL-4, IL-5, IL-6, IL-10 and IL-13).

J Immunother Cancer. 2019 Feb 6;7(1):33.

Granta-519

0, 0.5, 1, 2, 4 µM

24-48 hours

To evaluate the cytotoxicity of Citarinostat and Momelotinib alone and in combination on Granta-519 cells. Results showed that Granta-519 cells were less sensitive to the combination treatment (CI > 1), exhibiting an antagonistic effect.

Apoptosis. 2020 Jun;25(5-6):370-387.

WSU-NHL

0, 0.5, 1, 2, 4 µM

24-48 hours

To evaluate the cytotoxicity of Citarinostat and Momelotinib alone and in combination on lymphoid malignant cell lines. Results showed that the combination of Citarinostat and Momelotinib exhibited synergistic effects (CI < 1) in most cell lines, significantly inhibiting cell viability and inducing apoptosis.

Apoptosis. 2020 Jun;25(5-6):370-387.

Citarinostat/西他司他动物实验

Species CB.17 SCID mice Mice	Animal Model H929 MM xenograft model KP lung cancer model	Administration	Dosage	Frequency	Description	References
CB.17 SCID mice	H929 MM xenograft model	Intraperitoneal injection	50 mg/kg (ACY-241), 1 mg/kg (pomalidomide)	Once daily for 42 consecutive days	To evaluate the effect of combination treatment with ACY-241 and pomalidomide on tumor growth in the H929 MM xenograft model. Results showed that combination treatment significantly inhibited tumor growth without significant toxicity or adverse effects.	PLoS One. 2017 Mar 6;12(3):e0173507.
Mice	KP lung cancer model	Intraperitoneal injection	25 mg/kg (ACY241), 10 mg/kg (Oxaliplatin)	ACY241 3 times/week for 3 weeks; Oxaliplatin 1 time/week for 6 weeks	To evaluate the therapeutic effect of ACY241 alone or in combination with Oxaliplatin, results showed that combination therapy significantly prolonged the survival of mice and enhanced the effector function of tumor-associated T cells.	Oncoimmunology. 2022 Feb 22;11(1):2042065.

Species

CB.17 SCID mice Mice

Animal Model

H929 MM xenograft model KP lung cancer model

Administration

Dosage

Frequency

Description

References

CB.17 SCID mice

H929 MM xenograft model

Intraperitoneal injection

50 mg/kg (ACY-241), 1 mg/kg (pomalidomide)

Once daily for 42 consecutive days

To evaluate the effect of combination treatment with ACY-241 and pomalidomide on tumor growth in the H929 MM xenograft model. Results showed that combination treatment significantly inhibited tumor growth without significant toxicity or adverse effects.

PLoS One. 2017 Mar 6;12(3):e0173507.

Mice

KP lung cancer model

Intraperitoneal injection

25 mg/kg (ACY241), 10 mg/kg (Oxaliplatin)

ACY241 3 times/week for 3 weeks; Oxaliplatin 1 time/week for 6 weeks

To evaluate the therapeutic effect of ACY241 alone or in combination with Oxaliplatin, results showed that combination therapy significantly prolonged the survival of mice and enhanced the effector function of tumor-associated T cells.

Oncoimmunology. 2022 Feb 22;11(1):2042065.

Citarinostat/西他司他参考文献

Citarinostat/西他司他实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.14mL

0.43mL

0.21mL

10.68mL

2.14mL

1.07mL

21.37mL

4.27mL

2.14mL

Citarinostat/西他司他技术信息

CAS号	1316215-12-9
分子式	C₂₄H₂₆ClN₅O₃
分子量	467.95
SMILES Code	O=C(C1=CN=C(N(C2=CC=CC=C2Cl)C3=CC=CC=C3)N=C1)NCCCCCCC(NO)=O
MDL No.	MFCD28023593

别名	ACY241; HDAC-IN-2
运输	蓝冰
InChI Key	VLIUIBXPEDFJRF-UHFFFAOYSA-N
Pubchem ID	53340426

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry, 2-8°C

溶解方案

细胞实验：

DMSO: 30 mg/mL(64.11 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

方案三

靶点

靶点	数值

HDAC8	HDAC8, IC50:137 nM
HDAC3	HDAC3, IC50:46 nM
HDAC6	HDAC6, IC50:2.6 nM
HDAC2	HDAC2, IC50:45 nM
HDAC1	HDAC1, IC50:35 nM

Citarinostat/西他司他 {[allProObj[0].p_purity_real_show]}

Citarinostat/西他司他纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Citarinostat/西他司他质控信息

Citarinostat/西他司他生物活性

Citarinostat/西他司他细胞实验

Citarinostat/西他司他动物实验

Citarinostat/西他司他参考文献

Citarinostat/西他司他实验方案

Citarinostat/西他司他技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

靶点	HDAC8 HDAC8, IC50:137 nM HDAC3 HDAC3, IC50:46 nM HDAC6 HDAC6, IC50:2.6 nM HDAC2 HDAC2, IC50:45 nM HDAC1 HDAC1, IC50:35 nM
描述	Citarinostat (ACY241) is an orally available, and highly selective inhibitor of HDAC6, showing an IC50 of 2.6 nM. Its selectivity extends across other HDAC isoforms as well, with IC50 values of 35 nM, 45 nM, 46 nM, and 137 nM for HDAC1, HDAC2, HDAC3, and HDAC8, respectively, suggesting its potential for anticancer applications^[1].
体内研究	Furthermore, in vivo studies reveal that Citarinostat, dosed at 50 mg/kg via intraperitoneal injection once daily for five days followed by a two-day break for three weeks, significantly inhibits tumor growth. This effect is observed in female athymic nude mice when Citarinostat is used in conjunction with NSC 125973, highlighting its therapeutic potential in cancer treatment when possibly combined with other anticancer agents.
体外研究	When administered to A2780 cells at a concentration of 300 nM for 24 hours, Citarinostat leads to notable hyperacetylation of α-tubulin, indicating the inhibition of HDAC6's tubulin deacetylase activity. Conversely, significant hyperacetylation of histone H3, a Class I HDAC target, is observed only at concentrations exceeding 1 μM. This delineates Citarinostat's capability for selective inhibition of HDAC6 at lower doses, while higher doses inhibit Class I HDAC isozymes^[1]. In terms of cytotoxicity, Citarinostat's IC50 values span from 4.6 to 6.1 μM in A2780 and TOV-21G ovarian cancer cells, as well as in MDA-MB-231 breast cancer cells. The data indicate that lower doses of Citarinostat up to 3 μM modestly reduce cell proliferation without triggering apoptosis. However, a higher dose of 10 μM markedly induces apoptosis and entirely halts proliferation^[1].

Citarinostat/西他司他 {[allProObj[0].p_purity_real_show]}

Citarinostat/西他司他 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Citarinostat/西他司他 质控信息

Citarinostat/西他司他 生物活性

Citarinostat/西他司他 细胞实验

Citarinostat/西他司他 动物实验

Citarinostat/西他司他 参考文献

Citarinostat/西他司他 实验方案

Citarinostat/西他司他 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Citarinostat/西他司他纯度/质量文件产品仅供科研

Citarinostat/西他司他质控信息

Citarinostat/西他司他生物活性

Citarinostat/西他司他细胞实验

Citarinostat/西他司他动物实验

Citarinostat/西他司他参考文献

Citarinostat/西他司他实验方案

Citarinostat/西他司他技术信息